Cognition during active methamphetamine use versus remission.

Abstract

OBJECTIVE:

To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a history of substance use disorder (CTLs).

METHOD:

MA-ACT (n = 36), MA-REM (n = 48), and CTLs (n = 62) completed the Neuropsychological Assessment Battery (NAB).

RESULTS:

The MA-ACT group did not perform significantly worse than CTLs on any NAB Index. The MA-REM group performed significantly (p < 0.050) worse than CTLs on the NAB Memory Index. The MA-ACT group performed significantly better than CTLs and the MA-REM group on the Executive Functions Index.

CONCLUSIONS:

Some cognitive deficits are apparent during remission from MA use, but not during active use; this may result in clinical challenges for adults attempting to maintain recovery and continue with treatment.

• Authors: Marilyn Huckans, Stephen Boyd, Grant Moncrief, Nathan Hantke, Bethany Winters, Kate Shirley, Emily Sano, Holly McCready, Laura Dennis, Milky Kohno, William Hoffman, Jennifer M Loftis
• Journal: Journal of clinical and experimental neuropsychology (J Clin Exp Neuropsychol) Vol. 43 Issue 6 Pg. 599-610 (08 2021) ISSN: 1744-411X [Electronic] England
• PMID: 34612792 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Methamphetamine

Topics

• Adult
• Amphetamine-Related Disorders (complications)
• Cognition
• Executive Function
• Humans
• Methamphetamine (adverse effects)
• Neuropsychological Tests